fda import alert 66-80 glp-1 green list Creates of GLP1 Drug Ingredients Approved for Entry in the US FDA Import Alert 66-80: GLP-1

M., Alkhaldi, R

J., Patel, P., et al

One of the most common phrases we hear is that GLP 1 & GIP therapy quiets the food noise. Many patients report an even greater reduction in cravings compared to GLP 1 alone

Pre-treatment: Measure morning resting heart rate for 5 days Calculate average baseline Record any existing caffeine or stimulant use During treatment: Measure resting heart rate 3 times weekly during dose escalation Continue at each dose for minimum 4 weeks before increasing If resting HR exceeds baseline by more than 15 BPM, hold dose for an additional 2 weeks If resting HR exceeds 100 BPM at rest on two or more measurements, consult physician Expected timeline: Weeks 1-8: minimal heart rate change at starting doses Weeks 8-24: gradual increase of 5-10 BPM at therapeutic doses Weeks 24+: stabilization and gradual decline toward baseline This is the approach most researchers follow successfully, and it aligns with the standard retatrutide dosing protocol used in clinical trials